Strontium kinetics were investigated in a group of 14 patients receiving 89Sr palliation for metastatic bone disease secondary to prostatic carcinoma. Using 85Sr as a tracer, total body strontium retention R(t) was monitored for a 3 month period following 89Sr administration, and at 90 days was foun
89Sr Therapy: Strontium plasma clearance in disseminated prostatic carcinoma
โ Scribed by Glen M. Blake; John F. Wood; Peter J. Wood; Maureen A. Zivanovic; Valerie J. Lewington
- Publisher
- Springer
- Year
- 1989
- Tongue
- English
- Weight
- 542 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0340-6997
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
The total strontium plasma clearance rate due to excretion through the kidneys and gut has an important influence on the absorbed does delivered to skeletal metastases and red bone marrow in patients receiving 89Sr radionuclide therapy for disseminated prostatic carcinoma. Although a measurement of
We present dosimetry for spinal metastases and red bone marrow in two patients who received 89Sr therapy for disseminated prostatic carcinoma. Absorbed dose to metastases was estimated by combining 85Sr gamma camera studies with computed tomographic measurements of bone mass, and doses of 20 cGy/MBq